Monopar Therapeutics (MNPR) stock
Close on Nov 11, 2026Market cap $481.46MP/E –Yield –
Monopar Therapeutics reported revenue of $0 for fiscal 2025. At the latest close the market valued the company at $481.46M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $481.46M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.79
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$20.60M
- EPS, diluted
- -$2.41
- Book value per share
- $14.84
- Diluted shares
- 9M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $71.78
- Open
- $72.87
- Day's range
- $70.80 – $72.87
- Volume
- 157,460
- Average volume (20 days)
- 136,536
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 0.78
- 52-week range
- $50.07 – $124.82
- RSI (14 days)
- 44.6
- Volatility (1 year)
- 63.8%
- Relative volume
- 0.80×
- WACC
- 8.8%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MNPR | S&P 500 | Difference | MNPR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.2% | -2.4% | −6.7 pts | ||
| 3 months | -37.3% | -1.2% | −36.2 pts | ||
| Year to date | +9.8% | +12.3% | −2.4 pts | ||
| 1 year | -14.0% | +12.4% | −26.5 pts | ||
| 3 years | +3791.0% | +78.8% | +3712.2 pts | +238.9% | +21.4% |
| 5 years | +186.3% | +75.2% | +111.2 pts | +23.4% | +11.9% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Monopar Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Update
- Update
About Monopar Therapeutics
Pharmaceutical Preparations
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Wilson disease and targeted radiopharmaceuticals for oncology. Its primary therapeutic asset is ALXN1840, an investigational oral small molecule designed to bind and remove copper in Wilson disease patients. The company's oncology pipeline consists of uPAR-targeted radiopharmaceutical candidates, including MNPR-101-Zr for diagnostic imaging, MNPR-101-Lu for radioimmunotherapy, and preclinical MNPR-101-Ac for treating advanced solid cancers. Monopar develops its pipeline through internal programs and strategic licensing, aiming to serve individuals affected by rare genetic disorders and advanced malignancies.
Company profile, executives and historyMonopar Therapeutics stock: common questions
What is Monopar Therapeutics's stock price?
MNPR closed at $71.73 on Nov 11, 2026, down 0.07% on the day. Over the past 52 weeks it traded between $50.07 and $124.82.
What is Monopar Therapeutics's market cap?
Monopar Therapeutics was worth $481.46M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MNPR's P/E ratio?
Monopar Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.41), so it has no meaningful P/E ratio.
How much revenue does Monopar Therapeutics make?
Monopar Therapeutics reported revenue of $0 for fiscal 2025.
Does Monopar Therapeutics pay a dividend?
No. Monopar Therapeutics has not paid a cash dividend over the last twelve months.
When does Monopar Therapeutics report earnings next?
Monopar Therapeutics is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MNPR stock performed over the past year?
Including dividends, MNPR returned -14.0% over the past year, against +12.4% for the S&P 500.
Who are Monopar Therapeutics's competitors?
Companies most similar to Monopar Therapeutics by business, industry and size include RLYB, MREO, CNSP, AMLX, ARWR.
See a number that looks wrong?